Florida Cancer Care

Boca Raton Plantation
p. 561.727.3800
f.  561.727.3810
p. 954.582.1850
f.  954.582.1860

Research

In early 2006, Dr. Tan-Chiu founded Florida Cancer Research Institute (FCRI). FCRI's staff and state-of-the-art facility offer FDA approved clinical research trials giving its patients alternatives other than generic therapies usually offered by other general oncologist. We encourage our patients and physicians to join our network and help make vital contributions to the development of new and better therapies for the treatment of cancer.

Disease Protocol Title Status
Metastatic Breast B3271002 - Pfizer
A phase 3 randomized, double-blind study of PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer
ACTIVE /
Open for Enrollment
Metastatic Breast CP-MGAH22-02
A single arm, open-label, phase 2 study of MGAH22 (fc optimized chimeric ANTI-HER-2 monoclonal antibody ) in patients with relapsed or refractory advanced breast cancer whose tumor express HER2 at the 2+ level by IHC and lackof evidence of HER2 gene amplification by fish
ACTIVE /
Open for Enrollment
Metastatic Breast E7839-A001-208
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
ACTIVE
Neoadjuvant Breast GSK 113172
A Double Blind, Randomized (2:1) Placebo-controlled Phase I/II study of Neoadjuvant treatment with WT1-A10 plus ASI5 Antigen-Specific Cancer Immunotherapeutic in combination with Standard Therapy in women with WT1-positive Stage II or Stage III breast cancer (Opening 4/28/2011)
ACTIVE
Neoadjuvant Breast GSK 113172 - (WTI-AS15-BRS-001)
Study of GSK 2302024A Antigen-Specific Cancer Immunotherapeutic combined with Standard Neoadjuvant Treatment in Patients with Positive WT1-positive Primary Invasive Breast Cancer.
ACTIVE /
Open for Enrollment
Metastatic Breast MONALEESA-2 - Novartis
A Randomized, Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Post-menopausal women with Hormone-receptor-positive, HER2-negative, Advanced Breast Cancer who no received no Prior Therapy.
ACTIVE /
Open for Enrollment
Adjuvant Breast PH3-01 - �PRESENT PROTOCOL� Galena Biopharma
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment.
ACTIVE /
Open for Enrollment
Metastatic Breast PUMA-NER-1301 - PUMA Biotechnology
The NALA Study Neratinib Against Lapatinib in Advanced Breast Cancer. A Phase III Trial of Neratinib plus Capecitabine Vs. Lapatinib + Capecitabine in Patients with Her-2 Positive Metastatic Breast Cancer who have received two or more prior metastatic regimen.
ACTIVE /
Open for Enrollment
Observational Study TCREG-001-00-V2-1209 - CARIS
A Registry of CARIS target now test results for evaluation of correlation with clinical outcomes for cancer
ACTIVE /
Open for Enrollment